Hardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated

Hardman & Co: Four components integrated

AVO's goal is to deliver an affordable and novel proton therapy system (PT), based on state-of-the-art technology developed originally at the world-renowned CERN. Achievement of major technical milestones has boosted confidence greatly, and the group remains on track with its strategy. AVO has successfully integrated the four types of structures that constitute the LIGHT accelerator and has overcome technical challenges. The proton beam has been recorded at an energy of 52MeV, sufficient to treat superficial tumours. With the distribution agreement in place for SE Asia, partnerships with both RaySearch and the STFC, and strengthening of its financing structure, AVO is now on a much firmer footing.

Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/four-components-integrated/

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.